Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2011 1
2012 1
2015 1
2016 1
2017 2
2018 1
2019 1
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M; LALREAN. Piñero F, et al. Among authors: alonso c. Liver Int. 2019 Jun;39(6):1033-1043. doi: 10.1111/liv.14041. Epub 2019 Feb 4. Liver Int. 2019. PMID: 30636361
Further adjustment with competing risk regression and propensity score matching was carried out. RESULTS: During a median follow-up of 16 months (IQR 8.9-23.4 months) since DAAs initiation, overall cumulative incidence of HCC was 0.02 (CI 0.01; 0.03) at 12 months …
Further adjustment with competing risk regression and propensity score matching was carried out. RESULTS: During a median follow-up of 16 …
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M; Latin American Liver Research; Educational and Awareness Network (LALREAN). Mendizabal M, et al. Among authors: alonso c. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2554-2563.e3. doi: 10.1016/j.cgh.2020.02.044. Epub 2020 Feb 28. Clin Gastroenterol Hepatol. 2020. PMID: 32113892
Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models. RESULTS: During a median follow-up period of 26.2 months (interquartile range, 15.3-37.5 mo), the overall cumulative incidence of disease progr …
Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models. RESULTS: D …
Developing Transdermal Applications of Ketorolac Tromethamine Entrapped in Stimuli Sensitive Block Copolymer Hydrogels.
Mallandrich M, Fernández-Campos F, Clares B, Halbaut L, Alonso C, Coderch L, Garduño-Ramírez ML, Andrade B, Del Pozo A, Lane ME, Calpena AC. Mallandrich M, et al. Among authors: alonso c. Pharm Res. 2017 Aug;34(8):1728-1740. doi: 10.1007/s11095-017-2181-8. Epub 2017 May 24. Pharm Res. 2017. PMID: 28540502 Free article.
Finally, in vivo anti-inflammatory efficacy and skin tolerance were also assessed. RESULTS: HGs were transparent and kept stable after 3 months exhibiting biocompatible near neutral pH values. Rheological patterns fitted to Herschel-Bulkley for KT-C940-HG and Newton for KT …
Finally, in vivo anti-inflammatory efficacy and skin tolerance were also assessed. RESULTS: HGs were transparent and kept stable after 3 …
Molecular diagnosis of epileptic encephalopathy of the first year of life applying a customized gene panel in a group of Argentinean patients.
Juanes M, Veneruzzo G, Loos M, Reyes G, Araoz HV, Garcia FM, Gomez G, Alonso CN, Chertkoff LP, Caraballo R. Juanes M, et al. Among authors: alonso cn. Epilepsy Behav. 2020 Oct;111:107322. doi: 10.1016/j.yebeh.2020.107322. Epub 2020 Jul 20. Epilepsy Behav. 2020. PMID: 32702657
METHODS: We included 17 patients with EE with age of onset under 12 months without known etiology after ruling out structural abnormalities, metabolic disorders, and large chromosomal abnormalities. ...
METHODS: We included 17 patients with EE with age of onset under 12 months without known etiology after ruling out structural abnorma …
Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma.
Torbidoni AV, Laurent VE, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Rossi J, de Dávila MT, Alonso C, Alonso DF, Chantada GL. Torbidoni AV, et al. Among authors: alonso c. JAMA Ophthalmol. 2015 Jul;133(7):805-12. doi: 10.1001/jamaophthalmol.2015.0900. JAMA Ophthalmol. 2015. PMID: 25928893
Seventeen patients with metastatic retinoblastoma (9 at diagnosis, 8 at relapse; age range: 18-41 months) were included. MAIN OUTCOMES AND MEASURES: Detection of CRX mRNA as a marker for metastatic retinoblastoma and MD in bone marrow and CSF and its correlation with clini …
Seventeen patients with metastatic retinoblastoma (9 at diagnosis, 8 at relapse; age range: 18-41 months) were included. MAIN OUTCOME …
Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival.
Laurent VE, Torbidoni AV, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Garcia de Davila MT, Ramirez-Ortiz MA, Alonso CN, Rossi J, Alonso DF, Chantada GL. Laurent VE, et al. Among authors: alonso cn. JAMA Ophthalmol. 2016 Dec 1;134(12):1374-1379. doi: 10.1001/jamaophthalmol.2016.4158. JAMA Ophthalmol. 2016. PMID: 27787537
DESIGN, SETTING, AND PARTICIPANTS: This single-institution cohort study of patients with nonmetastatic retinoblastoma and HRPFs used prospectively defined inclusion criteria and a sampling strategy to procure bone marrow (BM) and cerebrospinal fluid (CSF) samples from May 1, 2007 …
DESIGN, SETTING, AND PARTICIPANTS: This single-institution cohort study of patients with nonmetastatic retinoblastoma and HRPFs used prospec …
Lineage switch in childhood acute leukemia: an unusual event with poor outcome.
Rossi JG, Bernasconi AR, Alonso CN, Rubio PL, Gallego MS, Carrara CA, Guitter MR, Eberle SE, Cocce M, Zubizarreta PA, Felice MS. Rossi JG, et al. Among authors: alonso cn. Am J Hematol. 2012 Sep;87(9):890-7. doi: 10.1002/ajh.23266. Epub 2012 Jun 8. Am J Hematol. 2012. PMID: 22685031 Free article.
Switches were suggested by morphology and confirmed with a median of 15 days (range: 8 days-6 months) from initiation of therapy. Of note, in five cases switches occurred before day 15. ...
Switches were suggested by morphology and confirmed with a median of 15 days (range: 8 days-6 months) from initiation of therapy. Of …
Hyperphosphatemia Promotes Senescence of Myoblasts by Impairing Autophagy Through Ilk Overexpression, A Possible Mechanism Involved in Sarcopenia.
Sosa P, Alcalde-Estevez E, Plaza P, Troyano N, Alonso C, Martínez-Arias L, Evelem de Melo Aroeira A, Rodriguez-Puyol D, Olmos G, López-Ongil S, Ruíz-Torres MP. Sosa P, et al. Among authors: alonso c. Aging Dis. 2018 Oct 1;9(5):769-784. doi: 10.14336/AD.2017.1214. eCollection 2018 Oct. Aging Dis. 2018. PMID: 30271655 Free PMC article.
BGP also reduced the proliferative capacity of cultured myoblasts. Old mice (24-months-old] presented higher serum phosphate concentration, lower forelimb strength, higher expression of p53 and ILK and less autophagy in vastus muscle than young mice (5-months-old]. …
BGP also reduced the proliferative capacity of cultured myoblasts. Old mice (24-months-old] presented higher serum phosphate concentr …
No benefit of Interfant protocols compared to BFM-based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina.
Pennella CL, Deu MA, Rossi JG, Baialardo EM, Alonso CN, Rubio P, Guitter MR, La Rosa CGS, Alfaro EM, Zubizarreta PA, Felice MS. Pennella CL, et al. Among authors: alonso cn. Pediatr Blood Cancer. 2020 Oct;67(10):e28624. doi: 10.1002/pbc.28624. Epub 2020 Jul 30. Pediatr Blood Cancer. 2020. PMID: 32729239
KMT2A-rearrangement status was the strongest prognostic factor (P = .048), independently of the protocol strategy. The median time for relapse was 24.1 months for patients with minimal residual disease (MRD)-negative versus 11.5 months for those with MRD-positive (P …
KMT2A-rearrangement status was the strongest prognostic factor (P = .048), independently of the protocol strategy. The median time for relap …
Second Neoplasms in Children Following a Treatment for Acute Leukemia and/or Lymphoma: 29 Years of Experience in a Single Institution in Argentina.
Felice MS, Rossi JG, Alonso CN, Rubio P, Gallego MS, Galluzzo ML, Lubieniecki F, Gutiérrez G, Guitter MR, Alderete DH, Rose AB, Cacciavillano WD, Herzovich V, Alfaro EM, Sánchez La Rosa CG, Millán N, Chantada GL, Figueroa Turienzo CM, Zubizarreta PA. Felice MS, et al. Among authors: alonso cn. J Pediatr Hematol Oncol. 2017 Nov;39(8):e406-e412. doi: 10.1097/MPH.0000000000000971. J Pediatr Hematol Oncol. 2017. PMID: 28945661
SN were AL (n=16), CNS tumors (n=5), endocrinal tumors (n=3), lymphomas (n=2), schwannoma (n=2) assorted sarcomas (n=4), retinal melanoma (n=1), and Vanek tumor (n=1). Median latency was 51 (range, 10 to 110) months for hematological malignancies and 119 (range, 25 to 236) …
SN were AL (n=16), CNS tumors (n=5), endocrinal tumors (n=3), lymphomas (n=2), schwannoma (n=2) assorted sarcomas (n=4), retinal melanoma (n …
13 results